TGTX - TG Therapeutics, Inc.
13.25 -0.30 (-2.21%)
After hours: 7:39PM EST
| Previous Close | 13.47 |
| Open | 13.34 |
| Bid | 13.54 x 800 |
| Ask | 13.70 x 800 |
| Day's Range | 12.95 - 13.66 |
| 52 Week Range | 3.87 - 14.89 |
| Volume | 2,404,010 |
| Avg. Volume | 2,175,587 |
| Market Cap | 1.349B |
| Beta (5Y Monthly) | 2.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.22 |
| Earnings Date | Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.60 |
- Simply Wall St.
TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Increased Their Holdings
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- Benzinga
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune ...
- GlobeNewswire
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting accelerated approval of umbralisib, the Company’s oral, once-daily, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma (MZL) and follicular lymphoma (FL). The Company has received guidance from the FDA that submission of a single NDA for both the MZL and FL indications is acceptable.
- Zacks
Options Traders Expect Huge Moves in TG Therapeutics (TGTX) Stock
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
- GlobeNewswire
TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 10, 2020 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- Zacks
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 8.9%
TG Therapeutics (TGTX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- Benzinga
The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...
- GlobeNewswire
TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor
TG Therapeutics, Inc. (TGTX), today announced it has entered into a definitive agreement to sell approximately 5.4 million shares of registered common stock of the Company at $9.20 per share, to a single, biotechnology-focused, institutional investor as a registered direct public offering. TG Therapeutics intends to use the net proceeds from the offering to fund the ongoing development and commercialization of the Company’s lead assets, ublituximab and umbralisib, as well as for research and development activities of the Company’s pipeline, and for general corporate purposes.
- Insider Monkey
Hedge Funds Are Crazy About TG Therapeutics Inc (TGTX)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- Zacks
TG Therapeutics' Shares Soar on Positive Early-Stage Data
TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.
- MarketWatch
TG Therapeutics shares rise on early-stage clinical data
Shares of TG Therapeutics Inc. gained 16% in premarket trading on positive data from small early-stage studies testing TG-1701 as a standalone therapy in patients with relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It also included TG-1701 as one of three experimental drugs developed by the company in a triple combination therapy for the same cancers. TG stock is up 73% year-to-date, compared to the S&P 500 , which has gained 25% during the same period. T
- GlobeNewswire
TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition
Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the lowest dose of TG-1701 tested Single.
- GlobeNewswire
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
TG Therapeutics, Inc. (TGTX), today announced triple therapy data from the Phase I/II study of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in combination with umbralisib (TGR-1202), the Company’s oral, dual inhibitor of PI3K delta and CK1 epsilon, and venetoclax, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Data from this trial were presented this morning during an oral session at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition.
- Benzinga
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
- GlobeNewswire
TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
TG Therapeutics, Inc. (TGTX), today recapped the schedule of triple therapy data presentations, at the upcoming 61st American Society of Hematology (ASH) annual meeting and exposition, to be held December 7 – 10, 2019, at the Orange County Convention Center in Orlando, FL.
- Thomson Reuters StreetEvents
Edited Transcript of TGTX earnings conference call or presentation 12-Nov-19 1:30pm GMT
Q3 2019 TG Therapeutics Inc Earnings Call
- GlobeNewswire
TG Therapeutics to Present at the Jefferies London Healthcare Conference
NEW YORK, Nov. 18, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
NEW YORK, Nov. 12, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2019 and recent company.
- GlobeNewswire
TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update
NEW YORK, Nov. 08, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday, November 12, 2019 at 8:30 AM ET to discuss.
- GlobeNewswire
TG Therapeutics Announces Triple Combination Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
100% overall response rate (ORR) in relapsed/refractory CLL patients (n=9) treated with U2 (umbralisib + ublituximab) plus venetoclax, with all patients at 12 months achieving.
- Insider Monkey
TG Therapeutics Inc (TGTX): Hedge Funds In Wait-and-See Mode
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
- TheStreet.com
2 Small Biotech Stocks Spurt Ahead on Positive Developments
The biotech sector has not been nearly as strong and is still off around 10% from the highs hit earlier in the year, as seen in the SPDR S&P Biotech ETF . TG Therapeutics should file another NDA for the treatment of Chronic Lymphocytic Leukemia, or CLL, in combination with its other late-stage compound TG-1101 sometime in the first half of 2020.
- GlobeNewswire
TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced that the follicular lymphoma (FL) cohort of the UNITY-NHL Phase 2b pivotal trial evaluating single agent umbralisib, the Company’s novel, once daily, PI3K delta inhibitor, met the primary endpoint of overall response rate (ORR) as determined by Independent Review Committee (IRC) for all treated patients (n=118) who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent. The results met the Company’s prespecified ORR target of 40-50%.
- GlobeNewswire
TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia as Compared to Ibrutinib Monotherapy
TG Therapeutics, Inc. (TGTX) today announced that final long-term results from the Phase 3 GENUINE study demonstrated that ublituximab in combination with ibrutinib improved progression-free survival (PFS), as determined by Independent Review Committee (IRC). The GENUINE Phase 3 study evaluated ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, compared to ibrutinib monotherapy in patients with relapsed/refractory high-risk chronic lymphocytic leukemia (CLL).
- Simply Wall St.
Is There An Opportunity With TG Therapeutics, Inc.'s (NASDAQ:TGTX) 30% Undervaluation?
In this article we are going to estimate the intrinsic value of TG Therapeutics, Inc. (NASDAQ:TGTX) by taking the...
